Art. -Nr.: HY-110133

JTE-607

6 Cited Publications

Kundenbewertung

Based on 6 publication(s) in Google Scholar

JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC₅₀s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively. Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Reinheit: 98.64%
CAS. Nr.: 188791-09-5
Formel: C₂₅H₃₃Cl₄N₃O₅
Molecular Weight:597.36

Speicherung:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

JTE-607 Chemical Structure

CAS. Nr.: 188791-09-5

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (6)
Lösungsmittel & Löslichkeit
- In Vitro
- In Vivo
Reinheit & Dokumentation
Verweise
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

JTE-607, a highly selective inflammatory cytokine synthesis inhibitor, protects from endotoxin shock in mice. JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC₅₀s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively^[1]. Cleavage and Polyadenylation Specificity Factor 3 (CPSF3) is the target of JTE-607^[2].

IC₅₀ & Target

IL-10

IL-6

IL-8

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

In Vitro

JTE-607 inhibits inflammatory cytokine production, including TNF-α, IL-1β, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC₅₀s of 11, 5.9, 8.8, 7.3 and 9.1 nM, respectively. The inhibitory effects of JTE-607 are also seen in mRNA expression of those cytokines^[1].
JTE-607 inhibits inflammatory cytokine production from LPS-stimulated human PBMCs with an IC₅₀ of approximately 10 nM^[1].
JTE607 inhibits LPS-stimulated IL-8 production from monkey and rabbit PBMCs, and TNF-α production from mouse and rat PBMCs with IC₅₀s of 59, 780, 1600 and 19000 nM, respectively^[1].
JTE607 also suppresses other cytokines, granulocyte-macrophage colony stimulating factor and IL-1RA with IC₅₀s of 2.4±0.8 and 5.4±0.4 nM, respectively^[1].
JTE-607 inhibits cytokine production in monkey, rabbit, mouse and rat with IC₅₀s of 59±26, 780±120, 1600±650 and 19000±3200 nM, respectively^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

RT-PCR^[1]

Cell Line:

human peripheral blood mononuclear cells (PBMCs)
Concentration:

100 nM
Incubation Time:

20 hours
Result:

Reduced the increase in the level of mRNAs of TNF-α, IL-1b, IL-6 and IL-8.

In Vivo

JTE-607 (0.3-10 mg/kg, i.v.) shows dose dependent inhibition of mortality after LPS challenge in C. parvum sensitized mice in accordance with a decrease of plasma TNF-α^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/6 mice (5 to 6 weeks old) are sensitized by injecting Corynebacterium parvum^[1]
Dosage:

0.3, 1, 3, 10 mg/kg
Administration:

Administered intravenously 10 min before the LPS challenge.
Result:

Showed dose dependent inhibition of the mortality at 0.3 to 10 mg/kg and significant effect at 3 and 10 mg/kg.

Chemical Information

CAS. Nr. 188791-09-5
Appearance Solid
Molecular Weight 597.36
Formel C₂₅H₃₃Cl₄N₃O₅
Color White to off-white
SMILES

CCOC([C@H](CC1=CC=CC=C1)NC(C2=C(C(Cl)=C(C(Cl)=C2)OCCN3CCN(CC3)C)O)=O)=O.Cl.Cl
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (6)

All Flow CytometryIn Vivo Efficacy StudyIHC

Sort by:

Journal Impact Factor

Cell Discov

RBBP6 maintains glioblastoma stem cells through CPSF3-dependent alternative polyadenylation. [Abstract]

2024 Mar 19;10(1):32. PMID: 38503731

JTE-607 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2024 Mar 19;10(1):32. [Abstract]

JTE-607 (7.143 μg per day per mouse; ICV) NSG immunocompromised mice suppressed tumor growth and prolonged mouse survival.

JTE-607 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2024 Mar 19;10(1):32. [Abstract]

JTE-607 (7.143 μg per day per mouse; ICV) in NSG immunocompromised mice suppressed tumor growth and prolonged mouse survival.

JTE-607 purchased from MedChemExpress. Usage Cited in: Cell Discov. 2024 Mar 19;10(1):32. [Abstract]

JTE-607 (7.143 μg per day per mouse; ICV) in NSG immunocompromised mice induced tumor cell apoptosis, as measured by the TUNEL assay.
Nucleic Acids Res

Transcription termination counteracts DNA damage after WEE1 inhibition. [Abstract]

2026 Jan 22;54(3):gkaf1487. PMID: 41569153

JTE-607 purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2026 Jan 22;54(3):gkaf1487. [Abstract]

Flow cytometry analysis of HeLa cells without (-) or with the indicated concentrations of JTE-607 (500 nM) and adavosertib (AZD1775) for 24 h. Numbers indicate γH2AX-positive cells.

JTE-607 purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2026 Jan 22;54(3):gkaf1487. [Abstract]

Flow cytometry analysis of pRNAPII S2 levels on chromatin in HeLa cells without (-) or with 1 μM JTE-607 for 2, 6, and 24 h (orange color).
Acta Pharm Sin B

DeepICER: A deep learning framework for predicting compound-induced gene expression profiles. [Abstract]

2026 May;16(5):2947-2963. PMID: 42180546
Acta Pharm Sin B

2026 Feb.
Cancer Lett

CPSF3 regulates alternative polyadenylation of CNIH2 to promote esophageal squamous cell carcinoma progression. [Abstract]

2024 Jul 1:593:216925. PMID: 38718887
Cell Rep

CPSF1 inhibition promotes widespread use of intergenic polyadenylation sites and impairs glycolysis in prostate cancer cells. [Abstract]

2025 Jan 22;44(1):115211. PMID: 39847481

Lösungsmittel & Löslichkeit

In Vitro:

DMSO : 250 mg/mL (418.51 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 20 mg/mL (33.48 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.6740 mL

8.3702 mL

16.7403 mL

5 mM

0.3348 mL

1.6740 mL

3.3481 mL

10 mM

0.1674 mL

0.8370 mL

1.6740 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.08 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.08 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.08 mg/mL (3.48 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 100 mg/mL (167.40 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Working solution concentration: 0.22 mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact

MedChemExpress (MCE) .

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (277 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. M Kakutani, et al. JTE-607, a novel inflammatory cytokine synthesis inhibitor without immunosuppression, protects from endotoxin shock in mice. Inflamm Res. 1999 Aug;48(8):461-8. [Content Brief]

[2]. Nathan T Ross, et al. CPSF3-dependent pre-mRNA processing as a druggable node in AML and Ewing's sarcoma. Nat Chem Biol. 2020 Jan;16(1):50-59. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	1.6740 mL	8.3702 mL	16.7403 mL	41.8508 mL
	5 mM	0.3348 mL	1.6740 mL	3.3481 mL	8.3702 mL
	10 mM	0.1674 mL	0.8370 mL	1.6740 mL	4.1851 mL
	15 mM	0.1116 mL	0.5580 mL	1.1160 mL	2.7901 mL
	20 mM	0.0837 mL	0.4185 mL	0.8370 mL	2.0925 mL
	25 mM	0.0670 mL	0.3348 mL	0.6696 mL	1.6740 mL
	30 mM	0.0558 mL	0.2790 mL	0.5580 mL	1.3950 mL
DMSO	40 mM	0.0419 mL	0.2093 mL	0.4185 mL	1.0463 mL
	50 mM	0.0335 mL	0.1674 mL	0.3348 mL	0.8370 mL
	60 mM	0.0279 mL	0.1395 mL	0.2790 mL	0.6975 mL
	80 mM	0.0209 mL	0.1046 mL	0.2093 mL	0.5231 mL
	100 mM	0.0167 mL	0.0837 mL	0.1674 mL	0.4185 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Keywords

JTE-607

6 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

JTE-607

Differentiation Inducing Compound Library

Pyroptosis Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Immunology/Inflammation Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) JTE-607

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

JTE-607

Differentiation Inducing Compound Library

Pyroptosis Compound Library

Angiogenesis-Related Compound Library

Antidepressant Compound Library

Anti-Prostate Cancer Compound Library

Chemokine Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Autoimmune Disease Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Immunology/Inflammation Compound Library

Clinical Compound Library

Drug Repurposing Compound Library

Publications Citing Use of MedChemExpress (MCE) JTE-607

Alle Interleukin Related Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (6)

Lösungsmittel & Löslichkeit

Reinheit & Dokumentation

Verweise

Help & FAQs

Complete Stock Solution Preparation Table

JTE-607 Related Classifications

HY-110133 Related Classifications